Nurix Therapeutics Net Income 2019-2021 | NRIX

Nurix Therapeutics net income from 2019 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Nurix Therapeutics Annual Net Income
(Millions of US $)
2020 $-43
2019 $-22
2018 $-9
Nurix Therapeutics Quarterly Net Income
(Millions of US $)
2021-08-31 $-29
2021-05-31 $-26
2021-02-28 $-24
2020-11-30 $-20
2020-08-31 $-19
2020-05-31 $8
2020-02-29 $-12
2019-08-31 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.249B $0.018B
Nurix Therapeutics a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics based in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48